There are currently 1268 clinical trials in Seattle, Washington looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Washington, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center and University of Washington Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Hybrid Type 2 Trial of Trauma-Focused Cognitive Behavioral Therapy and a Pragmatic Individual-Level Implementation Strategy
NCT04451161
Recruiting
This research project is a hybrid type 2 effectiveness-implementation trial that simultaneously examines (1) the effectiveness of a trauma-focused intervention for youth in the education sector and (2) the impact of a theory-driven pragmatic implementation strategy designed to increase the adoption, fidelity, and sustainment of evidence-based treatments (EBTs). This trial will include 120 clinicians and 480 students, and it is designed to test the cost effectiveness and impact of Trauma-Focused... Read More
Gender:
All
Ages:
Between 7 years and 85 years
Trial Updated:
11/27/2023
Locations: University of Washington, Seattle, Washington
Conditions: Evidence-Based Practices, CBT, School Health Services, Trauma, Psychological
Register for Updates
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
NCT04260022
Recruiting
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (BP) or with Ph+ ALL, who have experienced resistance or intolerance to at least two tyrosine kinase inhibitors (TKIs) or in subjects with Ph+ B-cell precursor (BCP) ALL or lymphoid blast phase CML (CML LBP), who have experienced resistance or intolera... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Fred Hutchinson Cancer Research Center, Seattle, Washington
Conditions: Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia
Register for Updates
Poststroke Depression in Hemorrhagic Stroke
NCT03826875
Recruiting
A double-blinded placebo-controlled randomized trial to evaluate the effect of preventative treatment of depression in survivors of aneurysmal subarachnoid hemorrhage (aSAH), a type of stroke.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
11/27/2023
Locations: Harborview Medical Center, Seattle, Washington
Conditions: Stroke Hemorrhagic, Depression
Register for Updates
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT05119335
Recruiting
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Seattle Cancer Care Alliance, Seattle, Washington
Conditions: ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell
Register for Updates
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
NCT05286788
Recruiting
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
11/27/2023
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
Register for Updates
Stroke and CPAP Outcome Study 3
NCT06029959
Recruiting
A problem with breathing during sleep, called obstructive sleep apnea (OSA), likely increases the risk of stroke and is common in people who have had a stroke, present in about 2/3 of stroke survivors. There is also evidence that OSA predicts worse outcome after stroke. The question being addressed in the Stroke and CPAP Outcome Study 3 (SCOUTS3) is how to improve use of continuous positive airway pressure (CPAP) therapy to treat OSA when started during intensive stroke rehabilitation.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: University of Washington, Seattle, Washington
Conditions: Ischemic Stroke, Intra Cerebral Hemorrhage, Obstructive Sleep Apnea, Adherence, Treatment, Motivation
Register for Updates
Casting vs Bracing for Idiopathic Early-Onset Scoliosis
NCT04500041
Recruiting
Comparison of casting and bracing for the treatment of idiopathic early onset scoliosis
Gender:
All
Ages:
Between 12 months and 36 months
Trial Updated:
11/27/2023
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Scoliosis Idiopathic, Early-Onset Scoliosis Deformity of Spine
Register for Updates
CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes
NCT03350828
Recruiting
This is a multicenter, cross-sectional, cohort study which will collect contemporary sweat chloride (SC) values from approximately 5000 Cystic Fibrosis (CF) patients prescribed and currently receiving commercially approved Cystic Fibrosis transmembrane conductance regulator (CFTR) modulator therapies.
Gender:
All
Ages:
4 months and above
Trial Updated:
11/21/2023
Locations: Seattle Children's Hospital, Seattle, Washington +1 locations
Conditions: Cystic Fibrosis
Register for Updates
The GBA Multimodal Study in Parkinson's Disease
NCT04101968
Recruiting
This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessm... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
11/20/2023
Locations: University of Washington, Seattle, Washington
Conditions: Parkinson Disease, GBA Gene Mutation, Gaucher Disease
Register for Updates
The Pediatric Anesthesia Quality Improvement Project
NCT00674388
Recruiting
The Study is designed to collect information about adverse events that occur in children undergoing anesthesia in participating hospitals. Demographic information will be collected on all anesthetics. An analysis of each adverse event will be performed and entered into the database. From this information we will devise strategies to prevent these adverse events.
Gender:
All
Ages:
21 years and below
Trial Updated:
11/20/2023
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Surgery, Anesthesia, Children
Register for Updates
Bolster: Caregiver App to Reduce Duration of Untreated Psychosis
NCT04949542
Recruiting
The proposed research project aims to develop and test a mobile health intervention designed to improve caregivers' illness knowledge and caregiving skills through interactive cognitive-behavioral modules, and through these improvements, reduce distress, improve coping, improve family communication, increase caregiver treatment facilitation and reduce duration of untreated psychosis. This clinical trial will involve a remote pilot randomized controlled trial comparing this new intervention to ex... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
11/17/2023
Locations: Behavioral Research in Technology and Engineering Center, Health Sciences, UW Medical Center, Seattle, Washington
Conditions: Caregiver to a Young Adult With Early Psychosis
Register for Updates
Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.
NCT04839991
Recruiting
FIH, Phase 1, open-label, multi centre study of CB307, a trispecific Humabody® T-cell enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours to assess safety and tolerability to determine MTD and preliminary RP2D.In addition this study will assess the safety and efficacy of CB307 when given in combination with pembrolizumab (KEYTRUDA®) in patients with metastatic PSMA+ castration-resistant cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: University of Washington, Seattle, Washington
Conditions: Advanced and/or Metastatic Solid Tumours
Register for Updates